The extra buffer protects against the compounding of side effects that comes from overlapping doses
Perez-Garcia A, Hurtado-Carneiro V, Herrero-De-Dios C, Dongil P, Garcia-Maurino JE, Sanchez MD, et al
Direct Medication Delivery: Get tirzepatide delivered to your door promptly
26%) and steatosis (31% vs
These benefits have been demonstrated in large, well-designed cardiovascular outcome trials, including: Liraglutide (Victoza) the LEADER trial , which showed a significant reduction in cardiovascular death and all-cause mortality Semaglutide (Ozempic) the SUSTAIN-6 trial , demonstrating fewer major adverse cardiovascular events, particularly stroke Dulaglutide (Trulicity) the REWIND trial , which showed a significant reduction in major cardiovascular events even in people without established cardiovascular disease Tirzepatide (Mounjaro) cardiovascular outcome data from the SURPASS-CVOT programme are emerging, with early results suggesting cardiovascular benefit compared with insulin therapy These cardiovascular effects are a key reason why GLP-1based therapies are now recommended earlier in the treatment pathway for people with type 2 diabetes who have established heart disease or are at high cardiovascular risk
For researchers dealing with constipation from GLP-1 medications , evening dosing can also be beneficial
